Endothelial cell infection and endotheliitis in COVID-19

The Lancet

Volumn 395, Issue 10234, 2020, Pages 1417-1418

  Varga, Zsuzsanna ^a   Flammer, Andreas J ^b   Steiger, Peter ^a   Haberecker, Martina ^a   Andermatt, Rea ^a   Zinkernagel, Annelies S ^a   Mehra, Mandeep R ^c   Schuepbach, Reto A ^a   Ruschitzka, Frank ^b   Moch, Holger ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; APOPTOSIS; ARTIFICIAL VENTILATION; AUTOPSY; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONAVIRUS DISEASE 2019; DETERIORATION; DIABETES MELLITUS; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; ENDOTHELIAL CELL INFECTION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIALITIS; ENDOTHELIITIS; FEMALE; HEART ARREST; HEART RIGHT VENTRICLE FAILURE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; INFLAMMATION; INFLAMMATORY CELL; INTESTINE NECROSIS; LETTER; LYMPHOCYTIC ENDOTHELIITIS; MALE; MESENTERIC ISCHEMIA; MIDDLE AGED; MONONUCLEAR CELL; MULTIPLE ORGAN FAILURE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RESPIRATORY FAILURE; SHOCK; SMALL INTESTINE RESECTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VIRUS INCLUSION; VIRUS INFECTION;

EID: 85083837578     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(20)30937-5     Document Type: Letter

References (11)

1. Zhou, F, Yu, T, Du, R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395 (2020), 1054–1062.
2. Horton, R, Offline: COVID-19—bewilderment and candour. Lancet, 395, 2020, 1178.
3. Ferrario, CM, Jessup, J, Chappell, MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111 (2005), 2605–2610.
4. Monteil, V KH, Prado, P, Hagelkrüys, A, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell, 2020 published online in press. https://www.cell.com/pb-assets/products/coronavirus/CELL_CELL-D-20-00739.pdf. (Accessed 17 April 2020)
5. Flammer, AJ, Anderson, T, Celermajer, DS, et al. The assessment of endothelial function: from research into clinical practice. Circulation 126 (2012), 753–767.
6. Bonetti, PO, Lerman, LO, Lerman, A, Endothelial dysfunction - a marker of atherosclerotic risk. Arterioscl Throm Vas 23 (2003), 168–175.
7. Anderson, TJ, Meredith, IT, Yeung, AC, Frei, B, Selwyn, AP, Ganz, P, The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332 (1995), 488–493.
8. Taddei, S, Virdis, A, Ghiadoni, L, Mattei, P, Salvetti, A, Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens 16 (1998), 447–456.
9. Flammer, AJ, Sudano, I, Hermann, F, et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 117 (2008), 2262–2269.
10. Hurlimann, D, Forster, A, Noll, G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106 (2002), 2184–2187.
11. Feldmann, M, Maini, RN, Woody, JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet, 2020 published online April 9. https://doi.org/10.1016/S0140-6736(20)30858-8.